Full Generic Medicine Info
Dosage/Direction for Use

Peripheral vascular disease
Adult: For the treatment of cases such as intermittent claudication, night cramps, rest pain, Raynaud's syndrome, incipient gangrene, trophic ulcers, diabetic arteriopathy and acrocyanosis: 100-200 mg tid. Alternative recommended dose for Raynaud's syndrome: As tab: 200 mg bid. Dosing recommendations may vary among countries and individual products (refer to specific product guidelines).
Should be taken with food. Take w/ a large glass of water.
History of hyperoxaluria or recurrent Ca-containing renal stones.
Special Precautions
Renal and hepatic impairment. Patient Counselling Administer with an adequate amount of fluid, particularly if taken before lying down. Ensure sufficient fluid intake during treatment to reduce the risk of kidney stones.
Adverse Reactions
Significant: Local oesophagitis (when taken without liquid before lying down); rarely, liver damage; very rarely, Ca oxalate kidney stones. Gastrointestinal disorders: Nausea, vomiting, epigastric pain, diarrhoea. Skin and subcutaneous tissue disorders: Rash.
Symptoms: Convulsions, depression of cardiac conductions. Management: Perform gastric lavage and induce emesis. May administer activated charcoal if needed. Monitor CV function and respiration. For severe cases, may consider electrical pacemaking or administration of isoprenaline. May give diazepam for convulsions.
Naftidrofuryl, a 5-HT2 receptor antagonist, produces vasodilation on both peripheral and cerebral circulation. It also activates intracellular aerobic metabolism which may provide cell protection against metabolic effects of ischaemia by increasing ATP levels and reducing lactic acid levels. Furthermore, it is a potent spasmolytic agent. Synonym: nafronyl.
Absorption: Well absorbed. Bioavailability: 17-32%. Time to peak plasma concentration: 30-45 minutes (cap); 2-3 hours (tab).
Distribution: Plasma protein binding: 92%, mainly albumin.
Metabolism: Primarily metabolised via hydrolysis into inactive metabolites.
Excretion: Via urine (80% as metabolites). Elimination half-life: 0.8-1.6 hours (cap); 3-4 hours (tab).
Oral: Store below 25°C. Protect from moisture and light.
CIMS Class
Peripheral Vasodilators & Cerebral Activators
ATC Classification
C04AX21 - naftidrofuryl ; Belongs to the class of other peripheral vasodilators.
Disclaimer: This information is independently developed by CIMS based on naftidrofuryl from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in